Factors affecting response to ECP
. | No. . | (%) . | CR/PR . | OR . | 95% CI . | P . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| 50 or younger | 48 | (76) | 27 | — | — | — |
| Older than 50 | 15 | (24) | 10 | 1.6 | 0.5-5.2 | .5 |
| Sex | ||||||
| Female | 30 | (48) | 17 | — | — | — |
| Male | 33 | (52) | 20 | 1.2 | 0.4-3.2 | .7 |
| Donor type | ||||||
| Matched sibling | 38 | (60) | 22 | — | — | — |
| Other | 21 | (33) | 12 | 1 | 0.35-3.0 | .9 |
| Diagnosis | ||||||
| ALL | 2 | (3) | 1 | — | — | — |
| AML/MDS | 23 | (37) | 12 | 1.8 | 0.2-1.5 | .2 |
| CML/MPD | 21 | (33) | 14 | 2 | 0.5-6.2 | .3 |
| Lymphoma | 13 | (21) | 9 | 0.5 | 0.5-8.6 | .3 |
| Aplastic anemia | 2 | (3) | 0 | — | — | — |
| Sickle-cell anemia | 1 | (2) | 1 | — | — | — |
| Breast cancer | 1 | (2) | 0 | — | — | — |
| GVHD prophylaxis | ||||||
| Tacrolimus/MTX | 57 | (90) | 28 | — | — | — |
| Tacrolimus/steroids | 5 | (8) | 4 | — | — | — |
| Cyclosporine/MTX | 1 | (2) | 0 | — | — | — |
| Acute GVHD | ||||||
| Grades 2-4 | 33 | (54) | 15 | 1.05 | 0.35-3.1 | .9 |
| Grades 0-1 | 30 | (46) | 21 | — | — | — |
| Steroids at ECP | ||||||
| No | 11 | (17) | 6 | — | — | — |
| Yes | 52 | (82) | 31 | 1 | 0.3-3.7 | .9 |
| No. prior treatments* | ||||||
| 2 | 40 | (63) | 26 | — | — | — |
| 3 | 23 | (37) | 11 | 0.5 | 0.2-1.4 | .2 |
| Type of chronic GVHD | ||||||
| De novo | 17 | (27) | 13 | — | — | — |
| Progressive | 16 | (25) | 7 | 0.2 | 0.05-1.1 | .06 |
| Relapsing | 30 | (48) | 17 | 0.4 | 0.1-1.5 | .2 |
| Organ involvement | ||||||
| No skin | 13 | (21) | 9 | 2.25 | 0.5-10.05 | .3 |
| Skin only | 30 | (48) | 18 | 1.5 | 0.5-4.9 | .5 |
| Skin and visceral | 18 | (29) | 9 | — | — | — |
| Skin and eyes/mouth | 2 | (3) | 1 | — | — | — |
| Scleroderma† | 21 | (33) | 14 | 2.1 | 0.7-6.9 | .2 |
| Response to first-line immunosuppression | ||||||
| CR/PR | 7 | (11) | 5 | 1.9 | 0.3-10.5 | .5 |
| Other | 56 | (89) | 32 | — | — | — |
| Platelet count | ||||||
| Less than 100 000/mm3‡ | 24 | (38) | 10 | 0.3 | 0.1-0.95 | .04 |
| 100 000/mm3 or more | 38 | (60) | 26 | — | — | — |
| Unknown | 1 | (2) | — | — | — | |
| LDH | ||||||
| 1000 IU/L or less | 41 | (65) | 27 | — | — | — |
| More than 1000 IU/L | 20 | (32) | 8 | 0.3 | 0.1-1.04 | .06 |
| Unknown | 2 | (3) | — | — | — |
. | No. . | (%) . | CR/PR . | OR . | 95% CI . | P . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| 50 or younger | 48 | (76) | 27 | — | — | — |
| Older than 50 | 15 | (24) | 10 | 1.6 | 0.5-5.2 | .5 |
| Sex | ||||||
| Female | 30 | (48) | 17 | — | — | — |
| Male | 33 | (52) | 20 | 1.2 | 0.4-3.2 | .7 |
| Donor type | ||||||
| Matched sibling | 38 | (60) | 22 | — | — | — |
| Other | 21 | (33) | 12 | 1 | 0.35-3.0 | .9 |
| Diagnosis | ||||||
| ALL | 2 | (3) | 1 | — | — | — |
| AML/MDS | 23 | (37) | 12 | 1.8 | 0.2-1.5 | .2 |
| CML/MPD | 21 | (33) | 14 | 2 | 0.5-6.2 | .3 |
| Lymphoma | 13 | (21) | 9 | 0.5 | 0.5-8.6 | .3 |
| Aplastic anemia | 2 | (3) | 0 | — | — | — |
| Sickle-cell anemia | 1 | (2) | 1 | — | — | — |
| Breast cancer | 1 | (2) | 0 | — | — | — |
| GVHD prophylaxis | ||||||
| Tacrolimus/MTX | 57 | (90) | 28 | — | — | — |
| Tacrolimus/steroids | 5 | (8) | 4 | — | — | — |
| Cyclosporine/MTX | 1 | (2) | 0 | — | — | — |
| Acute GVHD | ||||||
| Grades 2-4 | 33 | (54) | 15 | 1.05 | 0.35-3.1 | .9 |
| Grades 0-1 | 30 | (46) | 21 | — | — | — |
| Steroids at ECP | ||||||
| No | 11 | (17) | 6 | — | — | — |
| Yes | 52 | (82) | 31 | 1 | 0.3-3.7 | .9 |
| No. prior treatments* | ||||||
| 2 | 40 | (63) | 26 | — | — | — |
| 3 | 23 | (37) | 11 | 0.5 | 0.2-1.4 | .2 |
| Type of chronic GVHD | ||||||
| De novo | 17 | (27) | 13 | — | — | — |
| Progressive | 16 | (25) | 7 | 0.2 | 0.05-1.1 | .06 |
| Relapsing | 30 | (48) | 17 | 0.4 | 0.1-1.5 | .2 |
| Organ involvement | ||||||
| No skin | 13 | (21) | 9 | 2.25 | 0.5-10.05 | .3 |
| Skin only | 30 | (48) | 18 | 1.5 | 0.5-4.9 | .5 |
| Skin and visceral | 18 | (29) | 9 | — | — | — |
| Skin and eyes/mouth | 2 | (3) | 1 | — | — | — |
| Scleroderma† | 21 | (33) | 14 | 2.1 | 0.7-6.9 | .2 |
| Response to first-line immunosuppression | ||||||
| CR/PR | 7 | (11) | 5 | 1.9 | 0.3-10.5 | .5 |
| Other | 56 | (89) | 32 | — | — | — |
| Platelet count | ||||||
| Less than 100 000/mm3‡ | 24 | (38) | 10 | 0.3 | 0.1-0.95 | .04 |
| 100 000/mm3 or more | 38 | (60) | 26 | — | — | — |
| Unknown | 1 | (2) | — | — | — | |
| LDH | ||||||
| 1000 IU/L or less | 41 | (65) | 27 | — | — | — |
| More than 1000 IU/L | 20 | (32) | 8 | 0.3 | 0.1-1.04 | .06 |
| Unknown | 2 | (3) | — | — | — |
ALL indicates acute lymphoblastic leukemia; AML/MDS, acute myelogenous leukemia/myelodysplastic syndrome; CML/MPD, chronic myelogenous leukemia/myeloproliferative disorders; MTX, methotrexate; OR, odds ratio; and —, not applicable.
Including tacrolimus or cyclosporine.
When skin was the only organ involved.
100 000 mm3 is equal to 100 × 109/L.